



## **Autolus Therapeutics to participate in Investor Conferences through January**

January 4, 2021

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

- **11 January 2021** – The company will present at the **H.C. Wainwright BioConnect 2021 Conference** which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company's website at [Autolus](https://www.autolus.com).
- **13 January 2021** – The company will present at the **39th Annual J.P. Morgan Healthcare Conference** on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company's website at [Autolus](https://www.autolus.com).

Archived replays will be available for a period of 30 days after the conferences.

### **About Autolus Therapeutics plc**

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit [www.autolus.com](https://www.autolus.com).

### **Contact:**

Lucinda Crabtree, PhD  
Vice President, Investor Relations and Corporate Communications  
+44 (0) 7587 372 619  
[l.crabtree@autolus.com](mailto:l.crabtree@autolus.com)

Julia Wilson  
+44 (0) 7818 430877  
[j.wilson@autolus.com](mailto:j.wilson@autolus.com)

Susan A. Noonan  
S.A. Noonan Communications  
+1-212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)